Menu
Close
Home
About ImmuneOnco
About Us
Core Team
Development Strategy
ESG Report
Scientific Technology and R&D
Technology Platform
Product Pipeline
Latest Development
Company News
Investor Relations
Information Disclosure
Presentations
Corporate Governance
Investor Calendar
IR Contact
Join Us
Contact Us
Global
CN
TC
Home
CN
TC
About ImmuneOnco
About Us
Core Team
Development Strategy
ESG Report
Scientific Technology and R&D
Technology Platform
Product Pipeline
Scientific News
Company News
Investor Relations
Information Disclosure
Corporate Governance
Investor Calendar
Presentation Materials
Stock Information
Analyst Coverage
IR Contact
Email Subscription Center
Join Us
Contact Us
>
×
Company News
Home
Company News
News detail
ImmuneOnco Biopharmaceuticals' IMM2520 project completes first subject dosing
2023-03-23
726
Previous article：
ImmuneOnco Biopharmaceuticals IMM47, IMM2520 and IMM2510 invention patents were granted by the State Intellectual Property Office of China
Next article：
ImmuneOnco Biopharmaceuticals' IMM47, IMM40H, IMM2520, and IMM2902 projects debut at the 2023 American Association for Cancer Research (AACR) Annual Meeting
Back
Hot recommendation
2025-04-03
The National Medical Products Administration of the People’s Republic of China (the “NMPA”) Has Accepted the Group’s Application for a Clinical Trial of IMC-003/IMM72 for the Treatment of Pulmonary Arterial Hypertension (PAH)
More
2025-03-06
Approval by the NMPA for Clinical Trial of IMM01 (timdarpacept) Combined with IMM2510 (palverafusp α) and with or without Chemotherapy for Advanced Malignant Tumors
More
2025-01-13
ImmuneOnco IMM2510 Combined with Chemotherapy for First-Line NSCLC Treatment Completes Enrollment of First Patient in Phase Ib/II Clinical Trial
More
For more information
Please follow the official wechat public account
2023-03-23
726
